2012); (Pathipati et al. 2011), improves cognition (Nguyen et al. 2021), and synergizes with interferon‐β in MS therapy (Zhornitsky et al. 2015). In spinal muscular atrophy (SMA) models, PRL improves motor function and survival (Farooq et al. 2011), while in kainate‐induced epilepsy, PRL reduces seizure severity (Tejadilla et al. 2010). The gene discussed is PRL; the disease is spinal muscular atrophy.